Genmab To Expand Proprietary Pipeline, Closing In On Marketing Its Own Products
Updates Financial Guidance For 2021
Executive Summary
The antibody discovery and development biotech Genmab is preparing to commercialize its own products in the second half of 2021, as revenues continue to grow from partners and licensees.
You may also be interested in...
J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.